Wikipedia

Rory Collins

Sir Rory Edwards Collins FMedSci FRS[1] (born 3 January 1955) is a British physician who is Professor of Medicine and Epidemiology at the Clinical Trial Service Unit within the University of Oxford, the head of the Nuffield Department of Population Health and a Fellow of Green Templeton College, Oxford. His work has been in the establishment of large-scale epidemiological studies of the causes, prevention and treatment of heart attacks, other vascular disease, and cancer, while also being closely involved in developing approaches to the combination of results from related studies ("meta-analyses").[6][7][8] Since September 2005, he has been the Principal Investigator and Chief Executive of the UK Biobank,[3][4][5] a prospective study of 500,000 British people aged 40–69 at recruitment.

Sir Rory Collins
Born
Rory Edwards Collins

(1955-01-03) 3 January 1955 (age 69)[2]
Hong Kong[2]
Alma mater
Known forUK Biobank[3][4][5]
Awards
Scientific career
Fields
InstitutionsUniversity of Oxford
Websitewww.ndph.ox.ac.uk/team/rory-collins

Education

edit

Collins was educated at Dulwich College[2] and studied Medicine at St Thomas's Hospital Medical School, part of the University of London (1974–1980), and Statistics at George Washington University from 1976 to 1977 and the University of Oxford from 1982 to 1983.[citation needed]

Career and research

edit

Since 1985, Collins has been co-director with Sir Richard Peto of the University of Oxford's Clinical Trial Services and Epidemiological Studies units. In 1996, he was appointed Professor of Medicine and Epidemiology at Oxford, supported by the British Heart Foundation. Since September 2005, he has also been acting as the Principal Investigator and Chief Executive of the UK Biobank,[3][4][5] a prospective study of 500,000 British people, aged 40–69 at recruitment.

Collins' work has been in the establishment of large-scale epidemiological studies of the causes, prevention and treatment of heart attacks, other vascular disease, and cancer.[9]

He has created and led large studies that transformed statins from esoteric drugs for familial hypercholesterolaemia into widely-used generics that prevent millions of heart attacks and ischaemic strokes annually. His large placebo-controlled trials and worldwide Cholesterol Treatment Trialists' meta-analyses confirmed that statins reduce the risk of heart attack, discovered that they reduce the risk of stroke, and demonstrated their safety and efficacy in many different types of patient.[1] His research has been funded by the Medical Research Council (MRC).[10]

Awards and honours

edit

Collins was knighted in the 2011 New Year Honours for services to science.[11] He was elected as a Fellow of the Academy of Medical Sciences in 2004 and a Fellow of the Royal Society (FRS) in 2015.[1] Collins was included in Time's 2024 list of 100 most influential people in health.[12]

References

edit
  1. ^ a b c d "Sir Rory Collins FMedSci FRS". London: Royal Society. Archived from the original on 17 November 2015. One or more of the preceding sentences incorporates text from the royalsociety.org website where:

    "All text published under the heading 'Biography' on Fellow profile pages is available under Creative Commons Attribution 4.0 International License.” --"Royal Society Terms, conditions and policies". Archived from the original on 25 September 2015. Retrieved 9 March 2016.{{cite web}}: CS1 maint: bot: original URL status unknown (link)
  2. ^ a b c "COLLINS, Sir Rory (Edwards)". Who's Who. Vol. 2016 (online Oxford University Press ed.). Oxford: A & C Black. (Subscription or UK public library membership required.)
  3. ^ a b c Sudlow, Cathie; Gallacher, John; Allen, Naomi; Beral, Valerie; Burton, Paul; Danesh, John; Downey, Paul; Elliott, Paul; Green, Jane; Landray, Martin; Liu, Bette; Matthews, Paul; Ong, Giok; Pell, Jill; Silman, Alan; Young, Alan; Sprosen, Tim; Peakman, Tim; Collins, Rory (2015). "UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age". PLOS Medicine. 12 (3): e1001779. doi:10.1371/journal.pmed.1001779. ISSN 1549-1676. PMC 4380465. PMID 25826379.
  4. ^ a b c Allen, N. E.; Sudlow, C.; Peakman, T.; Collins, R. (2014). "UK Biobank Data: Come and Get It". Science Translational Medicine. 6 (224): 224ed4. doi:10.1126/scitranslmed.3008601. ISSN 1946-6234. PMID 24553384. S2CID 206684216.
  5. ^ a b c Collins, Rory (2012). "What makes UK Biobank special?". The Lancet. 379 (9822): 1173–1174. doi:10.1016/S0140-6736(12)60404-8. ISSN 0140-6736. PMID 22463865. S2CID 205965558.
  6. ^ Rory Collins's publications indexed by the Scopus bibliographic database. (subscription required)
  7. ^ Collaboration, A. T. (2002). "Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients". BMJ. 324 (7329): 71–86. doi:10.1136/bmj.324.7329.71. ISSN 0959-8138. PMC 64503. PMID 11786451.
  8. ^ Heart Protection Study Collaborative Group (2002). "MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial". The Lancet. 360 (9326): 7–22. doi:10.1016/S0140-6736(02)09327-3. ISSN 0140-6736. PMID 12114036. S2CID 35836642.
  9. ^ Rory Collins' profile
  10. ^ "UK government grants awarded to Rory Collins". Swindon: Research Councils UK. Archived from the original on 18 December 2015.
  11. ^ "No. 59647". The London Gazette (Supplement). 31 December 2010. p. 1.
  12. ^ "TIME100 Health". TIME. Retrieved 16 September 2024.


 

This United Kingdom biographical article related to medicine is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Rory_Collins&oldid=1246045578"